StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.89+0.05 (+6.39%)

Close on Nov 19, 2026Market cap $69.44MP/E –Yield –

Cardiff Oncology gross margin

Gross margin is gross profit as a percentage of revenue.

Cardiff Oncology's gross margin for the twelve months ending Dec 31, 2019 was 100.0%. For fiscal 2019 it was 100.0%, against -57.9% the year before. The highest annual figure on record is 100.0% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2019Dec 31, 2019100.0%+157.9
FY2018Dec 31, 2018-57.9%+200.5
FY2017Dec 31, 2017-258.4%+95.7
FY2016Dec 31, 2016-354.1%−253.0
FY2015Dec 31, 2015-101.1%−195.6
FY2014Dec 31, 201494.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2019Dec 31, 2019100.0%+0.0
Q3 FY2019Sep 30, 2019100.0%+30.2
Q2 FY2019Jun 30, 2019100.0%+182.8
Q1 FY2019Mar 31, 2019100.0%+365.8
Q4 FY2018Dec 31, 2018100.0%+207.3
Q3 FY2018Sep 30, 201869.8%+353.5
Q2 FY2018Jun 30, 2018-82.8%+148.7
Q1 FY2018Mar 31, 2018-265.8%+282.8
Q4 FY2017Dec 31, 2017-107.3%+656.2
Q3 FY2017Sep 30, 2017-283.7%+93.3
Q2 FY2017Jun 30, 2017-231.5%–
Q1 FY2017Mar 31, 2017-548.6%–
Q4 FY2016Dec 31, 2016-763.6%–
Q3 FY2016Sep 30, 2016-377.0%–

More Cardiff Oncology figures

See a number that looks wrong?